IgG4相关性眼病患者眼外受累的危险因素及治疗结局
该研究回顾性分析了韩国三个三级转诊中心2009年1月至2015年3月期间经手术活检确诊的42例IgG4相关性眼病(IgG4-ROD)患者,发现双侧受累、症状持续时间较长和血清IgG4水平较高是眼外受累的显著危险因素;在眼外受累患者中,泼尼松龙联合免疫抑制剂预防复发的效果优于单用泼尼松龙。
要点
- 双侧受累、症状持续时间长、血清IgG4水平高是IgG4-ROD眼外受累的危险因素。
- 眼外受累患者中,联合免疫抑制治疗较单用激素显著降低复发率。
- 随访期间总复发率为37.1%。
核心结论
- 双侧受累、症状持续时间较长和血清IgG4水平较高是韩国IgG4-ROD患者眼外受累的显著危险因素。
- 在眼外受累患者中,泼尼松龙联合免疫抑制剂预防复发的效果优于单用泼尼松龙。
研究设计与样本
- 回顾性研究,纳入2009年1月至2015年3月7年间韩国三个三级转诊中心经手术活检确诊的42例IgG4-ROD患者。
主要发现
- 患者平均年龄55.2岁,男女比例1:1。
- 按主要受累眶内结构分类:泪腺炎52.4%,眶软组织炎症21.4%,三叉神经受累11.9%,肌炎9.5%。
- 眼外受累(n=21)与双侧受累(p=0.004)、症状持续时间较长(p=0.033)和血清IgG4水平较高(p=0.034)相关。
- 初始治疗方案包括密切观察(n=7)、单用泼尼松龙(n=22)和泼尼松龙联合免疫抑制剂(n=13)。
- 随访期间(平均24个月),13例患者(37.1%)出现复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: To analyse the clinical risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease (IgG4-ROD) in Korea. METHODS: We retrospectively reviewed medical records of 42 patients diagnosed with IgG4-ROD confirmed by a surgical biopsy during the 7-year period, between January 2009 and March 2015, at three tertiary referral centres in Korea. Data regarding patients' demographics, clinical characteristics and radiological findings were obtained. The relapse rate was compared between systemic steroids only and combined immunosuppressant therapy. RESULTS: The mean patient age was 55.2 years (male:female ratio, 1:1). Based on the primary orbital structure affected, the IgG4-RODs were classified as dacryoadenitis (52.4%), orbital soft tissue inflammation (21.4%), trigeminal nerve involvement (11.9%) and myositis (9.5%). Extraophthalmic involvement (n=21) was associated with bilateral involvement (p=0.004), longer symptom duration (p=0.033) and a higher serum IgG4 level (p=0.034). Initial treatment regimens included attentive observation (n=7), prednisolone alone (n=22) and prednisolone plus immunosuppressive agent (n=13). During follow-up (mean, 24 months), 13 patients (37.1%) experienced relapse. In the extraophthalmic involvement group, steroid therapy alone resulted in a significantly higher relapse rate than combined immunosuppressant treatment (p=0.028). CONCLUSION: Bilateral involvement, longer symptom duration and higher IgG4 levels were significant risk factors for extraophthalmic involvement in Korean patients with IgG4-ROD. In patients with an extraophthalmic involvement, prednisolone combined with an immunosuppressive agent was more effective for preventing recurrence than prednisolone alone.
引用
- Park J, Lee MJ, Kim N, et al. Risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease. Br J Ophthalmol. 2017. PMID: 28972022. doi:10.1136/bjophthalmol-2017-310584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。